Andrew Tsai
Stock Analyst at Jefferies
(4.87)
# 340
Out of 4,683 analysts
172
Total ratings
62.4%
Success rate
31.9%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Reiterated: Hold | $45 → $60 | $158.83 | -62.22% | 8 | Aug 19, 2026 | |
| NERV Minerva Neurosciences | Upgraded: Buy | $5 → $10 | $5.00 | +100.00% | 3 | Aug 14, 2026 | |
| DFTX Definium Therapeutics | Maintained: Buy | $65 | $44.81 | +45.06% | 6 | Aug 13, 2026 | |
| ANRO Alto Neuroscience | Maintained: Buy | $35 → $40 | $36.31 | +10.16% | 9 | Aug 13, 2026 | |
| AXSM Axsome Therapeutics | Maintained: Buy | $380 | $205.48 | +84.93% | 4 | Aug 11, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | $100 → $110 | $80.40 | +36.82% | 11 | Aug 11, 2026 | |
| BIIB Biogen | Maintained: Buy | $255 | $220.77 | +15.50% | 9 | Jul 30, 2026 | |
| ATAI AtaiBeckley | Downgraded: Hold | $10 → $7.5 | $7.44 | +0.81% | 13 | Jul 17, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $550 | $368.02 | +49.45% | 8 | Jun 30, 2026 | |
| HELP Cybin | Maintained: Buy | $22 | $13.99 | +57.31% | 2 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $14.88 | +20.97% | 2 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $145 | $79.49 | +82.41% | 1 | Apr 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $100 | $60.42 | +65.51% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $30 | $18.92 | +58.56% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 | $5.44 | +37.87% | 1 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $0.9 | $0.2484 | +262.32% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $33.46 | -10.34% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $12.54 | +155.18% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $5.15 | +94.17% | 7 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2.5 → $3 | $3.78 | n/a | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $0.85 | $2.34 | n/a | 2 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.5 | $5.60 | n/a | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $45.36 | n/a | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $35 | $51.17 | n/a | 3 | Dec 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $0.5 | $8.01 | n/a | 9 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 → $13 | $4.59 | n/a | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $26.34 | n/a | 5 | Jun 24, 2024 |
Moderna
Aug 19, 2026
Reiterated: Hold
Price Target: $45 → $60
Current: $158.83
Upside: -62.22%
Minerva Neurosciences
Aug 14, 2026
Upgraded: Buy
Price Target: $5 → $10
Current: $5.00
Upside: +100.00%
Definium Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $65
Current: $44.81
Upside: +45.06%
Alto Neuroscience
Aug 13, 2026
Maintained: Buy
Price Target: $35 → $40
Current: $36.31
Upside: +10.16%
Axsome Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $380
Current: $205.48
Upside: +84.93%
BridgeBio Pharma
Aug 11, 2026
Maintained: Buy
Price Target: $100 → $110
Current: $80.40
Upside: +36.82%
Biogen
Jul 30, 2026
Maintained: Buy
Price Target: $255
Current: $220.77
Upside: +15.50%
AtaiBeckley
Jul 17, 2026
Downgraded: Hold
Price Target: $10 → $7.5
Current: $7.44
Upside: +0.81%
Praxis Precision Medicines
Jun 30, 2026
Maintained: Buy
Price Target: $550
Current: $368.02
Upside: +49.45%
Cybin
Jun 25, 2026
Maintained: Buy
Price Target: $22
Current: $13.99
Upside: +57.31%
May 14, 2026
Maintained: Buy
Price Target: $18
Current: $14.88
Upside: +20.97%
Apr 12, 2026
Initiated Coverage: Buy
Price Target: $145
Current: $79.49
Upside: +82.41%
Mar 9, 2026
Rated: Buy
Price Target: $65 → $100
Current: $60.42
Upside: +65.51%
Jan 12, 2026
Maintained: Buy
Price Target: $35 → $30
Current: $18.92
Upside: +58.56%
Dec 31, 2025
Maintained: Hold
Price Target: $7.5
Current: $5.44
Upside: +37.87%
Dec 17, 2025
Downgraded: Hold
Price Target: $15 → $0.9
Current: $0.2484
Upside: +262.32%
Nov 24, 2025
Maintained: Buy
Price Target: $30
Current: $33.46
Upside: -10.34%
Nov 21, 2025
Initiated Coverage: Buy
Price Target: $32
Current: $12.54
Upside: +155.18%
Nov 11, 2025
Maintained: Buy
Price Target: $10
Current: $5.15
Upside: +94.17%
Aug 8, 2025
Maintained: Hold
Price Target: $2.5 → $3
Current: $3.78
Upside: n/a
Aug 6, 2025
Maintained: Hold
Price Target: $3 → $0.85
Current: $2.34
Upside: n/a
Mar 26, 2025
Maintained: Buy
Price Target: $8.5
Current: $5.60
Upside: n/a
Mar 12, 2025
Reiterated: Buy
Price Target: $40
Current: $45.36
Upside: n/a
Dec 7, 2024
Rated: Buy
Price Target: $35
Current: $51.17
Upside: n/a
Sep 18, 2024
Rated: Hold
Price Target: $3 → $0.5
Current: $8.01
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $75 → $13
Current: $4.59
Upside: n/a
Jun 24, 2024
Maintained: Buy
Price Target: $42
Current: $26.34
Upside: n/a